P/E at 34.78 vs Industry's 33.79: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Premium Reflecting Sector Confidence

The current P/E ratio of 34.78 for Sun Pharmaceutical Industries Ltd is marginally higher than the industry average of 33.79. This premium, while not excessive, suggests that investors are willing to pay a small premium for the company’s earnings relative to its peers. Given the large-cap status and market capitalisation of ₹4,32,600.10 crores, this valuation reflects confidence in the company’s earnings stability and growth prospects within the Pharmaceuticals & Biotechnology sector. However, the premium is modest enough to avoid the extremes seen in some other large-cap stocks trading at multiples well above 50x.

Performance Across Timeframes: Divergent Momentum Signals

Examining the stock’s returns across various timeframes reveals a complex momentum profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a positive return of 6.77%, outperforming the Sensex which declined by 5.56% during the same period. This outperformance extends to the year-to-date figure, where the stock gained 4.84% while the Sensex fell 10.11%. However, the shorter-term returns tell a different story. The stock’s one-month return is negative at -4.10%, underperforming the Sensex’s 1.82% gain, and the one-week return of 0.81% lags behind the Sensex’s 4.19%. The three-month return is almost flat at 0.14%, compared to the Sensex’s 2.74% rise. This divergence suggests that while the stock has shown resilience over longer periods, recent market dynamics have tempered its momentum — Sun Pharmaceutical Industries Ltd’s short-term underperformance raises the question: is this a temporary correction or a sign of deeper challenges ahead?

Moving Average Configuration: Mixed Signals from Technical Indicators

The technical picture for Sun Pharmaceutical Industries Ltd is equally nuanced. The stock currently trades above its 5-day, 50-day, 100-day, and 200-day moving averages, indicating underlying strength and support at these levels. However, it remains below the 20-day moving average, a shorter-term indicator that often signals near-term momentum shifts. This configuration suggests a recent bounce within a broader consolidation phase rather than a clear breakout or breakdown. The four-day consecutive gain, amounting to a 2.55% rise, supports the notion of a short-term recovery — is this a genuine recovery or a relief rally that will fade at the 20 DMA? — the moving average configuration provides the clearest answer.

Sector Performance Context: Pharmaceuticals & Biotechnology Showing Mixed Results

The Pharmaceuticals & Biotechnology sector has seen 35 stocks declare results recently, with 19 reporting positive outcomes, 9 flat, and 7 negative. This distribution indicates a broadly stable sector environment with a majority of companies delivering positive or steady results. Within this context, Sun Pharmaceutical Industries Ltd’s performance aligns with the sector’s overall resilience. The stock’s ability to outperform the Sensex over one year and year-to-date periods reflects its relative strength in a sector that is navigating a mixed earnings landscape.

Rating Reassessment: Previously Rated Hold, Now Updated

MarketsMOJO had previously rated Sun Pharmaceutical Industries Ltd as Hold. The rating was reassessed on 8 June 2026, reflecting updated analysis of the company’s fundamentals, valuation, and technical indicators. The reassessment comes amid the stock’s modest valuation premium and mixed short-term momentum, balanced by solid longer-term returns and a stable sector backdrop. This raises the question for investors: should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Balanced Valuation with Mixed Momentum and Technical Signals

In summary, Sun Pharmaceutical Industries Ltd presents a valuation profile that is slightly premium but broadly in line with its Pharmaceuticals & Biotechnology peers. Its one-year and year-to-date returns demonstrate resilience and outperformance relative to the Sensex, while shorter-term returns and technical indicators suggest a period of consolidation and mixed momentum. The sector’s overall positive result distribution supports the company’s stable positioning. The recent rating reassessment from Hold reflects these nuanced factors, leaving investors to consider the balance of valuation, performance, and technical outlook — what is the current rating for Sun Pharmaceutical Industries Ltd?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today